Canada is to ship  vials of its Ebola vaccine to the World Health Organization The jab can completely protect animals from a fatal dose of the Ebola virus However its safety and effectiveness in humans is unknown  Trials began in the US this week and the WHO will conduct further tests in Europe and Africa  The Public Health Agency of Canada said the vaccine could be an important tool in curbing the outbreak The recent Ebola outbreak  the largest in history  has killed more than  people in West Africa  By December up to  people a week could be being infected by the virus the WHO says  There is no cure or proven vaccine but a number of experimental approaches are being rushed through  The Canadian vaccine developed by the public health agency of Canadas National Microbiology Laboratory combines fragments of Ebola virus with a nonfatal virus It should be enough to trigger the immune system to produce antibodies to attack Ebola protecting against future infection Clinical trials have started at the Walter Reed Army Institute of Research in the US but results are not expected until December  Canada will begin shipping the  vials on Monday They will be sent in three batches as a precautionary measure The vaccine must be packed in dry ice and kept at C in order to remain viable  Further trials will take place in Germany Switzerland and countries in Africa not hit by the Ebola outbreak Dr Gregory Taylor the chief public health officer of Canada said This vaccine the product of many years of scientific research and innovation could be an important tool in curbing the outbreak  We will continue to work closely with the WHO to address some of the ethical and logistical issues around using this experimental vaccine in the fight against Ebola Around a third of the total stocks of the vaccine will be kept in Canada for research or compassionate use the Canadian government said  A separate vaccine is already being trialled in the US UK and Mali It is being made by GlaxoSmithKline which has warned the vaccine will come too late for the current epidemic Dr Ripley Ballou the head of GSKs Ebola vaccine research said full safety and effectiveness data would not be ready until late  At the same time we have to be able to manufacture the vaccine at doses that would be consistent with general use and thats going to take well into  to be able to do that he added I dont think this can be seen as the primary answer to this particular outbreak